Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Naprelan Generic Exclusivity Settled; Andrx Sees Three Near-Term Launches

Executive Summary

SkyePharma has waived its 180-day exclusivity for a generic version of Elan's Naprelan (naproxen), clearing the way for approval of Andrx' generic version of the product, Andrx says

Related Content

Wellbutrin SR Generics Multiply As Andrx Relinquishes Exclusivity
Wellbutrin SR/Zyban Generics Will Not Be Blocked By Andrx Exclusivity
Tidbits From First Quarter Conference Calls, In Brief
Elan Naprelan FTC subpoena
GSK Switch Success: Paxil CR Has 31% Of New Scripts; Augmentin ES, 49%
Cardizem CD settlement
Wellbutrin SR, Zyban appeal
Andrx Altocor Sales Force Expands 50%; Generic Prilosec Charge Is $41 Mil.
GSK’s X-Factor: Augmentin XR, Other Line Extensions Key To Growth
Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts